The QualityStocks Daily Monday, December 18th, 2023

Today's Top 3 Investment Newsletters

MarketClub Analysis(IVVD) $3.5900 +120.25%

QualityStocks(BMRA) $1.6500 +66.67%

FreeRealTime(ZIMV) $17.1000 +52.41%

The QualityStocks Daily Stock List

Biomerica Inc. (BMRA)

QualityStocks, MarketClub Analysis, MarketBeat, StockMarketWatch, StockEarnings, BUYINS.NET, TradersPro, InvestorPlace, Profitable Trader Authority, Buzz Stocks, Greenbackers, OTCtipReporter, Penny Pick Finders, PennyStockProphet, PennyStockScholar, Prism MarketView, Wall Street Resources, Stock Market Watch, StockOnion, StocksEarning, Streetwise Reports, The Online Investor and PennyTrader Publisher reported earlier on Biomerica Inc. (BMRA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Biomerica, Inc. (NASDAQ: BMRA) is a biomedical technology firm that is focused on the development, manufacture and marketing of diagnostic and therapeutic products for the treatment and/or detection of medical conditions.

The firm has its headquarters in Irvine, California and was incorporated in September 1971. It serves consumers across the globe.

The company’s mission is to improve the lives of people living with chronic diseases while lowering the overall cost of healthcare. It operates through the Middle East, South America, Asia, United States, Europe and Other geographical segments. Most of the company’s revenue is generated from the Europe market.

The enterprise’s diagnostic test kits are used to measure the level of particular antigens, antibodies, hormones, bacteria or other substances which exist in blood in minute concentrations or in a patient’s stool and body. They are also used to analyze fecal, urine or blood specimens from patients in the diagnosis of different ailments and medical complications. The enterprise primarily sells its products for diabetes, food intolerances, gastrointestinal disease and different esoteric tests at hospital and clinical labs, over-the-counter drugstores and physicians’ offices. The enterprise is also engaged in the development of Helicobacter pylori products; and an irritable bowel syndrome diagnostic-guided therapy and technology known as InFoods. In addition to this, it also develops, tests and sells diagnostic products for coronavirus infections.

The firm recently released its first quarter of fiscal year 2021 financial results, which show increases in net sales and revenue, as well as decreases in net loss. It is currently focused on the development of its H. pylori test, which may soon be approved by the FDA. Its approval will have a positive effect on the firm’s investments as well as its growth.

Biomerica Inc. (BMRA), closed Monday's trading session at $1.65, up 66.6667%, on 67,196,129 volume. The average volume for the last 3 months is 149,465 and the stock's 52-week low/high is $0.704/$3.80.

Skeena Resources (SKE)

Vantage Wire, MarketClub Analysis and MarketBeat reported earlier on Skeena Resources (SKE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Skeena Resources Limited (NYSE: SKE) (TSE: SKE) (FRA: RXF) is a mineral exploration firm focused on exploring for and developing mineral properties in Canada.

The firm has its headquarters in Vancouver, Canada and was incorporated in 1979, on September 13th. Prior to its name change in June 1990, the firm was known as Prolific Resources Limited. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm serves consumers in Canada.

The company primarily explores for gold, copper, silver, and other precious metal deposits. It is in the exploration stage with respect to its mineral property interests. The company has exploration and evaluation interests in Eskay Creek Property and Snip Property. It is focused on Eskay Creek gold-silver mine, which is located in Tahltan Territory in the Golden Triangle of northwest British Columbia, Canada. The Eskay Creek Property comprises of roughly 8 mineral leases, 2 surface leases and several unpatented mining claims totaling approximately7,096 hectares. The Snip Property is made up of a mining lease and more than 8 mineral claims totaling approximately 4,546 hectares in the Liard Mining Division. Its Snip Property has indicated resources that include more than 244,000 ounces of gold and has resources within the inferred category, including approximately 402,000 ounces of gold.

The firm, which recently reported its latest financial results, is currently focused on revitalizing the past-producing Eskay Creek mine and bringing it to production. This may bring revenues into the firm while also generating value for its shareholders.

Skeena Resources (SKE), closed Monday's trading session at $4.54, up 1.7937%, on 288,411 volume. The average volume for the last 3 months is 22,773 and the stock's 52-week low/high is $3.045/$7.65.

Nature Wood (NWGL)

We reported earlier on Nature Wood (NWGL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nature Wood Group Ltd. (NASDAQ: NWGL) is an integrated forestry firm focused on up-stream forest management and harvesting, and down-stream wood-processing and distribution activities.

The firm has its headquarters in Macau, China and was incorporated in 2011, on September 22nd. Prior to its name change in September 2022, the firm was known as China Nature Wood Industry Group Ltd. It operates as part of the lumber and wood production industry, under the basic materials sector. The firm serves consumers in China, Europe, North America, South Asia, and South America.

The company operates as a subsidiary of Easy Bliss Limited, through the Direct Purchase and Original Design Manufacturer; and Manufacturing segments. The Direct Purchase and Original Design Manufacturer segment provides sourcing of live wood and owning designs on wood products for sales to end customers. On the other hand, the Manufacturing Segment is focused on manufacturing decking, flooring, or sawn timbers.

The enterprise provides a range of products, including sawn timber, logs, decking and flooring products, machine-made charcoal, recycled and synthesized charcoal, and essential oils. It also offers IT and business consultancy services. It serves importers, retailers, and processors through its global sales network.

The firm recently provided an update on its financial performance, noting that it remained committed to its long-term strategy and was focused on operational efficiency, sustainable practices, and exploring new markets to strengthen its position as a leading player in the forestry and wood products industry. This will positively influence shareholder value as well as its overall growth.

Nature Wood (NWGL), closed Monday's trading session at $8.32, up 14.6006%, on 2,349 volume. The average volume for the last 3 months is 268,574 and the stock's 52-week low/high is $7.00/$14.30.

GD Culture (GDC)

INO Market Report and MarketClub Analysis reported earlier on GD Culture (GDC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GD Culture Group Limited (NASDAQ: GDC) is a holding firm that operates through its primary business conduit, AI Catalysis Corp.

The firm has its headquarters in Nevada and was incorporated in 2018, on February 6th. Prior to its name change in January 2023, the firm was known as Code Chain New Continent Ltd. It operates as part of the electronic gaming and multimedia industry, under the communication services sector. The firm serves consumers around the globe.

The company’s main businesses include AI-driven digital human technology; Live-streaming e-commerce; and Live streaming interactive games. Under its AI business division, it is focused on providing technology application services of digital human creation and customization for social media influencers or SMBs (Small and Medium-sized Businesses) in the consumer industry to help the clients optimize their online marketing and advertising. Under the e-commerce business, its focus is on capturing TikTok's popular trend by offering carefully selected product choices with smooth delivery, aiming to redefine the online shopping experience. It has formulated a dual strategy employing both short video and live streaming to afford online shoppers a more convenient and interactive shopping experience. On the other hand, the interactive game division is focused on diversifying its game offerings and the anchor personalities for TikTok users.

The firm, through its AI Catalysis subsidiary, announced recently that its portfolio company, DigiTrax Entertainment Inc. had unveiled a new AI Music Training Model License offered in its patented AI platform KR38R LAB’s Artist and Label Services. This move unlocks innovative AI-driven creative possibilities and may positively influence investments into the firm.

GD Culture (GDC), closed Monday's trading session at $3.0797, up 3%, on 144,272 volume. The average volume for the last 3 months is 1,917 and the stock's 52-week low/high is $1.80/$44.00.

Environmental Tectonics (ETCC)

MarketBeat, StockEarnings, Wall Street Mover,, PoliticsAndMyPortfolio, OTCPicks, Zacks, Timothy Sykes, QualityStocks, M2 Communications and FeedBlitz reported earlier on Environmental Tectonics (ETCC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Environmental Tectonics Corporation (OTC: ETCC) is an engineered solutions firm that is focused on designing, manufacturing and selling software driven products.

The firm has its headquarters in Southampton, Pennsylvania and was incorporated in 1969 by William F. Mitchell. It operates as part of the aerospace and defense industry, under the industrials sector. The firm serves consumers around the world, with a focus on those in the United States.

The enterprise operates in two segments; Aerospace Solutions (Aerospace) and Commercial/Industrial Systems (CIS). The Aerospace segment is focused on designing, manufacturing and selling aircrew training systems to commercial, governmental, and military defense agencies; providing advanced disaster management simulators to governmental organizations, original equipment manufacturers, fire and emergency training schools, universities, and airports, as well as training devices, including altitude and multiplace chambers to governmental and military defense agencies, and civil aviation organizations. It also offers integrated logistics support services. On the other hand, the CIS segment is involved in the design, manufacture, and sale of steam and gas sterilizers to medical device and pharmaceutical manufacturers, as well as universities; and environmental testing and simulation systems primarily to commercial automotive, as well as to heating, ventilation, and air conditioning manufacturers. This segment also offers parts, as well as upgrade, maintenance, and repair services. The enterprise markets its products through independent sales representatives and distributors.

The company recently announced its latest financial results, with its CEO noting that the increased backlog from its good performance along with its solid pipeline of opportunities positioned the company well moving forward.

Environmental Tectonics (ETCC), closed Monday's trading session at $0.744, up 17.6052%, on 256 volume. The average volume for the last 3 months is 403,044 and the stock's 52-week low/high is $0.22/$1.94.


Vantage Wire, Stockhouse,, MarketBeat, The Street and Streetwise Reports reported earlier on GRI Bio (GRI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GRI Bio Inc. (NASDAQ: GRI) is a clinical-stage biopharmaceutical firm focused on the treatment of inflammatory, fibrotic and autoimmune illnesses.

The firm has its headquarters in La Jolla, California and was incorporated in May 2009. Prior to its name change, the firm was known as Glycoregimmune Inc. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers across the globe, with a primary focus on the United States.

The company is focused on advancing a pipeline of Natural Killer T (NKT) modulating therapies which are based on NKT cells. These are key regulators earlier in the inflammatory cascade, to interrupt illness progression and restore the immune system to homeostasis. It has a library of more than 500 proprietary compounds targeting a number of high value indications with unmet need.

The enterprise's lead program, GRI-0621 is a small molecule RAR-beta dual agonist that inhibits the activity of human Type I, or invariant, NKT (iNKT) cells, which is being developed for the treatment of Idiopathic pulmonary fibrosis (IPF). This formulation is a once-daily oral capsule for several fibrotic indications. Its second asset, GRI-0803, is a novel activator of human Type 2 NKT cells in development for the treatment of autoimmune disorders, with an initial focus on systemic lupus erythematosus.

The firm’s GRI-0621 formulation recently received clearance from the FDA for its Investigational New Drug application for the treatment of IPF. This brings the firm closer to helping patients with this rare chronic progressive pulmonary illness while also opening it up to new growth and investment opportunities.

GRI Bio (GRI), closed Monday's trading session at $0.4364, off by 0.727934%, on 52,076 volume. The average volume for the last 3 months is 24,004 and the stock's 52-week low/high is $0.25/$13.33. Inc. (LTRY)

QualityStocks, StocksToBuyNow, SmallCapRelations, SeriousTraders,, InvestorPlace and The Online Investor reported earlier on Inc. (LTRY), and today we highlight the Company, here at the QualityStocks Daily Newsletter. (NASDAQ: LTRY, LTRYW), a leading technology company that is transforming how, where and when the lottery is played, has announced additional new funding as well as its plans to proceed with the acquisition of Nook Holdings Limited to further develop its brand in the Middle East. The company has enhanced its long-term growth and financial stability through entering into a placement agent agreement with Univest Securities LLC, under which Univest has introduced to new investors, resulting in an initial $1 million. The funds are being utilized as working capital and to restart’s core operations including the Nexus Gaming Platform, WinTogether and the LotteryLink(TM) affiliate program. The new investment is in addition to ongoing funding provided by United Capital Investments Limited (“UCIL”). “This latest infusion of funds and continued support from UCIL marks a pivotal moment for We are focusing on enhancing our technological infrastructure and customer experience, ensuring that as we restart operations, we do so with a system that is robust, scalable and ready to meet the evolving needs of our users,” said Gregory Potts, COO of “The support from our investors is not just a financial boost but also a vote of confidence in our operational capabilities and future vision.”

To view the full press release, visit

About Inc. is a leading technology company that is transforming how, where and when lottery is played. Its engaging mobile and online platforms enable players and commercial partners located in the United States and internationally to remotely purchase legally sanctioned lottery games. Fans and subscribers look to for compelling, real-time results on more than 800 lottery games from more than 40 countries. Additionally, through, is fundamentally changing how non-profit donors are incentivized to action by gamifying charitable giving. In all that it does,’s mission remains the same: an uncompromising passion to innovate, grow a new demographic of enthusiasts, deliver responsible and trusted solutions, and promote community and philanthropic initiatives. For more information about the company, visit Inc. (LTRY), closed Monday's trading session at $1.4, even for the day, on 44,703 volume. The average volume for the last 3 months is 1.283M and the stock's 52-week low/high is $1.32/$16.598.

HUB Cyber Security Ltd. (HUBC)

QualityStocks, MarketBeat, InvestorsUnderground, InvestorPlace, 360wallstreet and 247 Market News reported earlier on HUB Cyber Security Ltd. (HUBC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

HUB Cyber Security (NASDAQ: HUBC), a developer of confidential computing cybersecurity solutions and services is expanding its collaboration with a top global entertainment company; the expansion reflects the success of the ongoing partnership, the company noted. According to the announcement, the expansion includes the entertainment company integrating HUB Security's cybersecurity services across its global branches in order to fortify digital infrastructure and enhance protection against emerging cybersecurity threats. “We are excited to enhance our partnership with a renowned leader in the entertainment industry,” said HUB Cyber Security CEO Noah Hershcoviz in the press release. “This development is a testament to our previous achievements and also mirrors our joint dedication to pioneering solutions and security. HUB Security is keen to support our distinguished collaborator's ongoing prosperity in a world that's becoming ever more interconnected.”

To view the full press release, visit

About HUB Cyber Security Ltd.

HUB Cyber Security was established in 2017 by veterans of the elite intelligence units of the Israeli Defense Forces. The company specializes in unique cybersecurity solutions protecting sensitive commercial and government information. The company debuted an advanced encrypted computing solution aimed at preventing hostile intrusions at the hardware level while introducing a novel set of data-theft prevention solutions. HUB Security operates in more than 30 countries and provides innovative cybersecurity computing appliances, as well as a wide range of cybersecurity services worldwide. For more information about the company, please visit

HUB Cyber Security Ltd. (HUBC), closed Monday's trading session at $2.12, off by 7.8261%, on 255,386 volume. The average volume for the last 3 months is 1.763M and the stock's 52-week low/high is $1.873/$31.00.

Cronos Group Inc. (CRON)

InvestorPlace, Schaeffer's, Kiplinger Today, MarketClub Analysis, The Street, StocksEarning, MarketBeat, Daily Trade Alert, Trades Of The Day, Wealth Insider Alert, The Online Investor, QualityStocks, Market Intelligence Center Alert, StockMarketWatch, StreetInsider, StockEarnings, BUYINS.NET, Zacks, The Wealth Report, Top Pros' Top Picks, Stock Up Featured, Investopedia, Cabot Wealth, Daily Profit, InvestmentHouse, Early Bird, InsiderTrades, Jim Cramer, The Rich Investor, InvestorsObserver Team, VectorVest, Money Morning, TheTradingReport, 24/7 Trader, Wall Street Window, Small Cap Firm, Stock Gumshoe and InvestorsUnderground reported earlier on Cronos Group Inc. (CRON), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The Department of Health and Human Services (HHS) recently released a set of documents pertaining to its recommendation to move cannabis from Schedule I to III under the Controlled Substances Act (CSA). The documents also encompass an in-depth evaluation conducted by the health agency regarding the acknowledged medical value of marijuana.

Included in the newly revealed materials are correspondences from HHS officials to DEA administrator Anne Milgram and the rationale behind the recommended reclassification, backed by an exhaustive eight-factor analysis mandated by the CSA. Despite the release, a significant portion of the pages is heavily censored, and some have been entirely withheld.

The documents became accessible online, courtesy of attorneys Shane Pennington and Matt Zorn, coauthors of the On Drugs blog. Zorn had previously submitted a Freedom of Information Act (FOIA) request to obtain these records. In response, HHS scrutinized 252 pages, releasing only two pages in full. An additional 236 pages were partially redacted, and 14 were entirely withheld.

The disclosed documents broadly outline contemporary scientific findings that have emerged in recent years, after a previous denial of a petition to reschedule cannabis. HHS suggests that these developments may now warrant a reconsideration of cannabis scheduling.

The current examination primarily focuses on the modern scientific considerations surrounding currently accepted medical use (CAMU) for cannabis. It also delves into new epidemiological data regarding marijuana abuse, a perspective absent in the 2015 HHS evaluation of marijuana under the CSA’s eight-factor analysis.

HHS acknowledges the complexity of determining the abuse potential of cannabis, emphasizing that it involves multifaceted dimensions. The health agency underscores that there is no singular test or assessment that comprehensively characterizes the abuse potential, making it an intricate consideration.

HHS director of FOIA litigations and appeals, in a letter to Zorn, explained that redactions were made under a FOIA provision exempting intra-agency memoranda or letters not available by law to parties outside an agency engaged in litigation with the agency.

HHS had earlier released a highly redacted version of a one-page letter from the health agency to the DEA in response to public records requests by various entities, including lawyers and news organizations.

The attention has now shifted to the DEA, as it holds the rescheduling recommendation. While the Congressional Research Service (CRS) indicates a likelihood of the DEA following the HHS recommendation based on historical precedent, the DEA retains the authority to disregard the health agency’s advice due to its final jurisdiction over the CSA.

Marijuana businesses such as Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) are likely to analyze those released documents in order to glean insights into the possible policy direction that may emerge over the coming years.

Cronos Group Inc. (CRON), closed Monday's trading session at $1.88, off by 2.5907%, on 1,271,146 volume. The average volume for the last 3 months is 81,423 and the stock's 52-week low/high is $1.64/$2.88.

Bit Mining Ltd. (BTCM)

QualityStocks, MarketClub Analysis, StockEarnings, Schaeffer's, CryptoCurrencyWire, Wall St. Warrior, The Stock Dork, StocksEarning, smartmoneytrading, MarketBeat, INO Market Report and 247 Market News reported earlier on Bit Mining Ltd. (BTCM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BlackRock’s proposed Bitcoin (BTC) spot ETF is undergoing a key adjustment in its mechanics, opening up possibilities for Wall Street financial institutions to play a significant role. The recent modification allows authorized participants, essential players in the ETF ecosphere, to generate new fund shares using cash, a departure from the previous restriction to crypto-only creation.

This alteration holds particular significance for highly regulated American banks, which, due to current restrictions, cannot directly hold BTC. This adjustment creates an opportunity for institutions such as Goldman Sachs and JPMorgan, boasting some of the world’s largest balance sheets, to step in as APs for BlackRock’s ETF.

In the revised setup, the money deployed by APs may be converted to BTC through a middleman and held by the ETF’s custodian. This information was disclosed in a memo connected to a Nov. 28, 2023, meeting between the SEC, NASDAQ and BlackRock.

A pivotal aspect of BlackRock’s setup is its stance sidestepping market manipulation, a longstanding concern of the SEC regarding Bitcoin ETFs. This model is meticulously crafted to enhance investor protection, diminish transaction costs and streamline operational procedures.

There is a growing sense of optimism regarding the SEC approval of Bitcoin spot ETFs. This approval could be a transformative development for the crypto-asset sector, attracting a surge of investments from retail and institutional investors. The previous consensus was that APs would primarily be large market-making companies with crypto expertise, such as Jump Trading, Virtu and Jane Street, rather than conventional banks. However, this modification expands the potential participant pool, allowing banks to take part and diversify liquidity providers.

Companies such as Bitwise, Fidelity and Grayscale are also awaiting SEC judgments on their plans regarding their submitted Bitcoin ETF applications, and BlackRock’s situation is only one aspect of the bigger picture. These talks center on several redemption methods to strike a balance between investor protection and risk management.

Sui Chung, CEO of CF Benchmarks, emphasized the possible implications, saying that the pool of possible authorized participants will grow if SEC approves this updated dual model and that the liquidity supporting ETF shares might rise dramatically.

The collaboration between NASDAQ and BlackRock in presenting this concept to the regulator underscores the growing partnership between tech platforms and traditional financial entities in developing crypto-related products. If BlackRock’s initiative proves successful, it could pave the way for broader integration and acceptance of Bitcoin within the conventional financial sector.

Moreover, it may inspire other financial institutions to explore similar avenues, contributing to the ongoing legitimization of Bitcoin as a viable asset class. As more investment is attracted via these ETFs, it could have a positive effect on the broader crypto industry, including for entities such as Bit Mining Ltd. (NYSE: BTCM).

Bit Mining Ltd. (BTCM), closed Monday's trading session at $4, off by 0.744417%, on 188,050 volume. The average volume for the last 3 months is 485,457 and the stock's 52-week low/high is $1.40/$5.49.

Mind Medicine Inc. (MNMD)

QualityStocks, InvestorPlace, Schaeffer's, MarketBeat, The Wealth Report, The Street, The Stock Dork, MarketClub Analysis, Daily Trade Alert and Trades Of The Day reported earlier on Mind Medicine Inc. (MNMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Terran Biosciences, a drug developer based in New York, announced recently that it had obtained patent approval for its psychedelic drugs from the U.S. Patent and Trademark Office. The drugs, which have been designed to treat neurological and psychiatric disorders, are based on psilocybin, namely psilocybin edisylate and psilocybin HCI.

Terran Biosciences describes the drugs as the world’s first new polymorphs and salts of psilocybin, noting that the patents will include techniques for treating the aforementioned disorders.

Dr. Sam Clark, Terran CEO and founder, stated that the company was approaching its goal of providing patients with accessible and affordable psilocybin treatment options. Now, the company is focused on acquiring approval from the FDA for its psilocybin variations. It hopes to have the drugs on the market within five years after said authorization has been obtained.

Currently, the company supplies researchers with psychedelics for their studies and clinical trials.

In addition, the company also obtained approval for what it terms orally active prodrugs of 5-MeO-DMT and DMT. DMT, or N,N-dimethylltryptamine, is a psychedelic and hallucinogenic that occurs naturally in many animals and plants. When ingested, this drug is known to produce intense but brief psychedelic effects.

5-MeO-DMT is a psychedelic classified under tryptamines. This compound can be found in the glands of the Sonoran desert toad or Colorado river toad. Similar to other tryptamines, the compound is used as an entheogen in South America. These psychedelics are generally injected or smoked, or they need a monoamine oxidase inhibitor to be activated orally. Terran has found a way to eliminate this requirement, however. The drugs are currently being tested in clinical trials, with the company noting that it is focused on acquiring FDA approval for these drugs as well.

In other news, the patent office also offered Terran Biosciences a notice of allowance for its ibogaine derivative. Ibogaine is a psychoactive substance found in plants in the Apocynaceae family, such as the Tabernanthe iboga shrub. This shrub is mainly found in central Africa. Ibogaine is known to be an effective treatment for substance-use disorder.

Currently, Terran Biosciences has one of the largest drug-development programs in the psychedelic industry. It is conducting experiments with varieties of psychedelics such as LSD, MDMA and 2CB for the treatment of a range of conditions.

This news from Terran Biosciences comes as psychedelic treatments continue to gain mainstream acceptance in the United States. Legislators from the House and Senate agreed to direct funding toward psychedelic research in a recently approved defense bill.

Many other companies, such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), are also focused on advancing the psychedelic medicine field, and we could soon see a flurry of new drug applications and patents being filed by these startups in the nascent industry.

Mind Medicine Inc. (MNMD), closed Monday's trading session at $3.54, up 5.6716%, on 1,175,842 volume. The average volume for the last 3 months is 617,938 and the stock's 52-week low/high is $2.12/$5.01.

Curaleaf Holdings Inc. (CURLF)

InvestorPlace, Kiplinger Today, MarketBeat, QualityStocks, Cabot Wealth, Daily Trade Alert, Top Pros' Top Picks, MarketClub Analysis, Profit Trends, The Online Investor, StreetInsider, Wealth Insider Alert, Early Bird, Trades Of The Day, Trading For Keeps, The Street, Investment U, Daily Profit, CFN Media Group, StreetAuthority Daily, Zacks, TradersPro, Wyatt Investment Research, wyatt research newsletter and Schaeffer's reported earlier on Curaleaf Holdings Inc. (CURLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Last week, South Dakota’s attorney general released a ballot explanation for a prospective initiative that would legalize adult-use cannabis in the state and allow dispensaries to serve individuals aged 21 years of age and older. The resolution, which was sponsored by Emmett Reistroffer, would permit anyone aged 21 and older to cultivate, possess, ingest and distribute cannabis or cannabis paraphernalia. Reistroffer is the operations director at Genesis Farms, a medical marijuana company.

Under the measure, adults could also grow no more than 6 marijuana plants, with not more than 12 plants in every household; the can also possess up to three ounces of cannabis. It is important to note that driving while under the influence of cannabis would still be illegal, as would marijuana-related activity by those below the age of 21.

According to the final explanation by Attorney General Marty Jackley, property owners and employers could still prohibit the use of cannabis under the measure. Additionally, sales would occur via existing medical cannabis dispensaries, which could acquire dual-use licenses via the Department of Health.

With regard to possession, adults could possess no more than 24g of concentrated marijuana as well as other nonconcentrated marijuana products that contained less than 2,400mg of THC.

For the resolution to qualify for the 2024 ballot, organizers will need to collect no less than 17,510 signatures from registered voters by May 2024. Once placed on the ballot, a majority vote would allow the measure to pass.

In his latest statement, Reistroffer noted that he had no plans to campaign or collect signatures for the resolution in 2024 because he didn’t want to compete with the other legalization initiative that was already collecting signatures with the aim of being included in next year’s ballot.

Meanwhile, organizers for the other legalization proposal received the AG’s final summary a couple of months ago. The proposal, which is sponsored by South Dakotans for Better Marijuana Laws, would allow those aged 21 years of age and older to distribute marijuana.  The initial form of this measure was amended to eliminate the word “sell.” This move made its language unclear, with the AG’s summary noting that legislative or judicial clarification was necessary.

A previous statement by Reistroffer highlighted some of the differences between his proposal and the South Dakotans for Better Marijuana Laws legalization measure. For instance, while his resolution included regulation and licensing via the health department, the other proposal did not touch on this matter.  Additionally, while Reistroffer’s proposal would establish a path to legal sales that would generate sales tax for the state, the other proposal would generate no taxes. Furthermore, while his proposal focused primarily on legal sales and regulations, the other resolution mainly centered on noncommercial legalization.

Many marijuana companies, such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF), may take an interest in the way the push to legalize cannabis in South Dakota plays out as the rift between different campaign groups could harm the reform movement.

Curaleaf Holdings Inc. (CURLF), closed Monday's trading session at $3.75, off by 3.599%, on 274,469 volume. The average volume for the last 3 months is 11,563 and the stock's 52-week low/high is $2.19/$5.80.

The QualityStocks Company Corner


The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

TikTok has received approval to revive its e-commerce business in Indonesia and will invest $840 million into purchasing most of Tokopedia, the e-commerce unit of Indonesian tech conglomerate GoTo. The purchase will allow the Chinese social media company to relaunch its online shopping business in Indonesia, the largest economy in southeast Asia. TikTok already had 6 million sellers as well as 7 million creator affiliates in Indonesia before Indonesian president Joko Widodo called for stricter social media regulations and stopped transactions on the social media app in early October. The social media company already had thousands of sellers on the platform; many of them lost hundreds of dollars in monthly income when Indonesia halted transactions on the platform. E-commerce in general, along with segments such as healthcare e-commerce, are attracting major investment inflows as exhibited by the growing footprint of entities such as NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW) in the major markets around the world. The move by TikTok to gain a major stake in Tokopedia is therefore unlikely to be an isolated occurrence.

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

  • E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
  • Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
  • NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
  • Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Monday's trading session at $1.69, up 5.625%, on 12,052 volume. The average volume for the last 3 months is 26,531 and the stock's 52-week low/high is $1.2115/$4.26.

Recent News

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)

The QualityStocks Daily Newsletter would like to spotlight Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF).

Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), a leading exploration and mine development company, is reporting on the first assay results from five of the 11 drill holes in its current definition drill program at the Iska Iska silver-tin polymetallic project, which is situated in southwestern Bolivia. According to the announcement, the drill hole results are "most encouraging" because they demonstrate substantive higher-grade intervals, especially for silver, in the potential starter pit mineral resource area, which may now be potentially upgraded and expanded. The definition diamond drill program is focused on upgrading and expanding the higher-grade Polymetallic ("Ag-Zn-Pb") Domain Type inferred mineral resource. "These latest drill hole results are very encouraging," said Eloro Resources CEO Tom Larsen in the press release. "They demonstrate substantive higher-grade intervals, especially for silver, in the potential starter pit mineral resource area that may now be potentially upgraded and expanded. Significant tin is present in several holes with grades up to 0.5%, highlighting the chances to expand and increase the grade of the tin resource, which is a high priority exploration target in 2024. As we expected, the higher-grade silver and tin intercepts from this definition drill program are demonstrating selective higher-grade metal zonation within the starter pit area and the Tin (‘Sn-Ag-Pb') domain. We expect to release results from the six remaining definition drill holes in the first part of January 2024, concluding our first phase infill definition drilling program aimed to enhance grade and expand tonnage in the Santa Barbara starter pit area."

To view the full press release, visit

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) is a publicly traded exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec.

The company has an option to acquire a 99% interest in the highly prospective Iska Iska Property, classified as a silver-tin polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department of southern Bolivia. Iska Iska is a road-accessible, royalty-free property.

Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the North-Central Mineral Belt of Peru, some 50 kilometers south of Barrick’s Lagunas Norte Gold Mine and Pan American Silver’s La Arena Gold Mine. La Victoria consists of eight mining concessions and eight mining claims encompassing approximately 89 square kilometers. La Victoria has good infrastructure, with access to road, water and electricity, and is located at an altitude that ranges from 3,150 meters to 4,400 meters above sea level.

The company has a strong management and technical team working diligently to uncover the value of both Iska Iska and La Victoria. Eloro is based in Toronto, Canada.


Iska Iska – Potosi, Bolivia

Iska Iska is associated with a Miocene possibly collapsed/resurgent caldera, emplaced on Ordovician age rocks with major breccia pipes, dacitic domes and hydrothermal breccias. The property is wholly controlled by the title holder, Empresa Minera Villegas S.R.L. It is located 48 kilometers north of Tupiza city, in the Sud Chichas Province of the Department of Potosi. This is an important mineral deposit type in the prolific South Mineral Belt of Bolivia. Eloro commissioned a NI 43-101 Technical Report on Iska Iska, which was completed by Micon International Limited and is available on Eloro’s website and under its filings on SEDAR.

A fully financed drill program is currently underway on the property, situated near world-class deposits including Silver Sand, San Bartolomé, Pulacayo, San Cristobal, San Vicente, Chorolque, Tasna, Choroma and Siete Suyos. Iska Iska is in the southwest part of the Eastern Cordillera, which hosts a number of major polymetallic mines and mineral deposits. Drilling and continuous channel sampling results have demonstrated some very high metal values, especially silver and tin, within an immense system, where mineralization has been encountered in every drill hole to date. The company believes there is excellent potential for world-class bulk mineable deposits.

La Victoria – Ancash, Peru

The La Victoria project, targeting gold and silver production, is situated near world-class, low-cost gold producers Pan American Silver and Barrick Gold Corporation. Located in Ancash Department, La Victoria sits on the western slopes of the Peruvian Andes. The property is located 12 hours from Lima, with a travel distance of 600 kilometers. The nearest road accessible population centers from La Victoria are Huandoval, Pallasca and Cabana. The project includes four principal mineralized zones in Peru’s prolific North-Central Mineral Belt – San Markito, Victoria, Victoria South and Ccori Orcco – with excellent potential for gold discovery. Operations at La Victoria are planned to proceed with a 2,000-meter diamond drilling program to test targets to outline potential resources at San Markito. Trenching and sampling confirmed high silver values and veins at San Markito in 2020.

Market Outlook

According to industry association The Silver Institute, the outlook for silver demand is exceptionally promising, with global demand forecast to rise to a record high of 1.112 billion ounces in 2022. The increase will be driven by record silver industrial fabrication, which is forecast to improve by 5%, as silver’s use expands primarily in solar energy and electric vehicle (EV) manufacturing. The institute states that government commitments to carbon neutrality have resulted in a rapid expansion of green energy projects, driving record photovoltaic panel installations which are expected to lift silver demand in this segment to an all-time high in 2022.

Rising demand in the electronics industry is also boosting the demand for tin, which is primarily used in solder. The electronics and electrical industries use solders containing 40-70% tin, which provide strong and reliable joints under a variety of environmental conditions. At present, the majority of the assemblers are using patented tin-and-copper-based solders. Mordor Intelligence estimated tin demand at 387 kilotons in 2021 and forecasts demand growth of 2.5% annually through 2027. Over the medium term, surging demand from the EV market and increasing applications in the electrical and electronics industry is expected to drive the market.

Management Team

Thomas G. Larsen is CEO of Eloro. He has more than 40 years of experience in the investment industry, specializing in corporate finance and management of junior resource companies, raising in excess of C$200 million. He previously held the position of President and Chief Executive Officer of Champion Iron Limited. Prior to that, he was President and Chief Executive Officer of Champion Iron Mines Limited.

Dr. Bill Pearson is Executive VP of Exploration for Eloro. He has more than 40 years of direct experience in the exploration and production of minerals worldwide. He played an integral role in the acquisitions of Desert Sun Mining Corp. by Yamana Gold in 2006 and Central Sun Mining by B2 Gold in 2009. He was formerly VP Exploration at Desert Sun Mining and Senior VP at Central Sun Mining.

Miles Nagamatsu, CPA, is CFO at Eloro. He has over 30 years of experience in accounting, management, lending, restructurings and turnarounds. Since 1993, he has acted as a CFO of public and private companies primarily in the mineral exploration and investment management sectors. He holds a Bachelor of Commerce degree from McMaster University.

Osvaldo Arce Burgoa is General Manager at Eloro. He is a geological and mineral processing engineer with 26 years of experience in Bolivia. He is a former President of the Bolivian Geological Society, Main Technical Advisor of the National Mining Corporation (COMIBOL) and has served as exploration manager and chief geologist at various mining and exploration companies. He has authored two books on Bolivian geology and holds a doctorate in mining engineering from Tohoku University in Sendai, Japan.

Eloro Resources Ltd. (OTCQX: ELRRF), closed Monday's trading session at $1.52, up 6.8917%, on 26,227 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.26/$.

Recent News

PaxMedica Inc. (NASDAQ: PXMD)

The QualityStocks Daily Newsletter would like to spotlight PaxMedica Inc. (NASDAQ: PXMD).

The CDC estimates 1 out of 36 children in the United States have been diagnosed with Autism Spectrum Disorder – with a therapeutic market potential of $3.42 billion by 2030

PaxMedica's mission is to help eliminate, reduce, or modulate the troublesome aspects of ASD, an unmet medical need in the industry

CEO Howard Weisman shared important updates and achievements in the company's pipeline, financial outlook, and future vision

In a 2020 report released by the Centers for Disease Control and Prevention ("CDC"), it was estimated that 1 out of 36 children had been diagnosed with autism spectrum disorder ("ASD") in the United States. While ASD is not uncommon, there are no pharmaceutical treatments approved to treat the disorder, only to manage the symptoms – which creates an unmet need in the industry. The ASD therapeutics market was valued at $1.93 billion in 2022 and is expected to reach $3.42 billion by 2030, growing at a CAGR of 7.9% ( It is essential to note that these estimates do not factor in the potential impact of treatments designed to address the core symptoms of ASD. PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on developing novel anti-purinergic therapies ("APTs") for the treatment of ASD and other serious conditions with intractable neurologic symptoms, is on a mission to help, reduce, and modulate some of the more challenging aspects of ASD. The company hopes to enable people with autism to integrate their behavior with others more successfully and improve their quality of life.

PaxMedica Inc. (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (APTs) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms.

The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself.

PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.

The company is headquartered in Tarrytown, New York.

Product Pipeline

PaxMedica is building a robust pipeline of products targeting ASD and related neurodevelopmental conditions. The company’s lead product in development may help eliminate, reduce or modulate some of the more troublesome aspects of ASD. That would open the potential for people with autism to integrate their behavior with others more successfully and improve their lives.

PaxMedica’s lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy that has been known for over 100 years. Its current pipeline includes:

  • PAX-101 (IV Suramin) for ASD – PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting APT and has reported positive results from a dose range study. The results of PaxMedica’s Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
  • PAX-102 (Intranasal Suramin) – PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
  • PAX-101 for HAT – Given suramin’s historical use as a treatment for Human African Trypanosomiasis (HAT), or African Sleeping Sickness, the company is also developing PAX-101 as a treatment for HAT. PaxMedica’s most advanced program is the pursuit of PAX-101 for early-stage East African HAT.
  • Selective APTs – PaxMedica has conducted several preclinical studies to evaluate other APTs that are more selective to specific purinergic receptors and may offer additional benefits over suramin.

Market Opportunity

According to a report by Fortune Business Insights, a leading global market research company, the global ASD therapeutics market was estimated at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, a CAGR of 7.9% over the forecast period. As there is no current treatment for the core symptoms of autism, PaxMedica believes the addressable market for PAX-101, if approved, could greatly exceed these forecasts.

Autistic disorder, Asperger’s Syndrome and Pervasive Development Disorder are the three main types of ASD, affecting millions of people globally. A 2020 report by the U.S. Centers for Disease Control & Prevention estimated that one in 36 children in the U.S. have been diagnosed with autism disorder.

Several factors are expected to contribute to market growth prospects. A growing prevalence of the condition globally and rising awareness coupled with available treatment options are key factors expected to drive ASD therapeutics market growth during the forecast period. Growing investment in R&D to find effective treatments is also expected to fuel global market growth.

Management Team

Howard Weisman is Chairman and CEO of PaxMedica. He has been a founder and CEO of several specialty pharma and medical device companies. Most recently, he was executive chairman and co-founder of Sofregen, a biotech company. He also served as CEO and president of Seventh Sense Biosystems, a medical device development company. He also was founder, chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company, and founder and COO of ESP Pharma, a company focused on cardio and neurovascular products. He has a bachelor’s degree in chemistry from Rutgers University.

David Hough, M.D., is Chief Medical Officer at PaxMedica. He is a neuroscience clinical development consultant who previously served as vice president at Janssen Research and Development and in various leadership roles over 17 years. Most recently, he was the compound development team leader for SPRAVATO® for treatment-resistant depression. Prior to that, he was the schizophrenia disease area leader. He played a pivotal role in the development programs for oral INVEGA®, INVEGA SUSTENNA® and XEPLION® for schizophrenia. He is a graduate of West Point and is board certified in psychiatry.

Stephen Sheldon is COO and CFO at PaxMedica. He has served as CEO of Thailand-based specialty healthcare company Indochina Healthcare Co. Ltd. since 2015. Previously, he was a consultant for PricewaterhouseCoopers Healthcare Advisory in the Chicago office. He was responsible for developing specialty pharmacy patient programs, strategy development for specialty products and compliance programs. He has an MBA from Thunderbird School of Global Management and a bachelor’s degree in computer science and visual arts from Bowdoin College.

PaxMedica Inc. (NASDAQ: PXMD), closed Monday's trading session at $0.8022, up 3.5097%, on 206,119 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.6384/$69.19.

Recent News

SenesTech Inc. (NASDAQ: SNES)

The QualityStocks Daily Newsletter would like to spotlight SenesTech Inc. (NASDAQ: SNES).

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, today announced its entry into a distribution agreement with Fruit Tree Limited, a Hong Kong-based pest control service provider, manufacturer and distributor. SenesTech is in the process of commercializing a proprietary technology for managing animal pest populations, primarily rat populations, through fertility control. The agreement with Fruit Tree Limited includes both a substantial initial stocking order and annual minimums. "Fruit Tree Ltd. is a leading company in the pest control industry, supplying products and services throughout the region, directly and through its subsidiaries, with a commitment to quality, innovation and sustainability," said Joel Fruendt, SenesTech's president and CEO. "As such, that makes them a perfect partner in this vital market, with Evolve(TM) the perfect addition to their portfolio of solutions."

To view the full press release, visit

SenesTech Inc. (NASDAQ: SNES) is the rodent fertility control expert and the inventor of the only EPA-registered contraceptive for male and female rats. The company’s technology provides an innovative and humane method for managing rat populations.

SenesTech is focused on developing effective solutions that are grounded in science and proven through research, all while providing value to people, communities and the environment. The company’s passion is to create a healthier world by better controlling rat pest populations. This aim is critical, as, if left unchecked, a breeding pair of rats and their descendants can produce up to 15,000 pups after just one year.

The company strives for clean cities, efficient businesses and happy households – with a product that was scientifically designed to be effective without killing rats. SenesTech is committed to the sustainable, humane treatment of animals, improving the quality of all human life and enhancing environmental stewardship through the global application of its effective solution in fertility control technology.

SenesTech is headquartered in Phoenix, Arizona.


SenesTech’s first product, ContraPest®, applies revolutionary technology to a global challenge that has persisted since the Middle Ages – the proliferation of rats in urban and agricultural settings. ContraPest® targets the reproductive capabilities of Norway and roof rats. As a highly palatable liquid, the formulation promotes sustained consumption, helping to reduce fertility in both male and female rats, bringing populations down and keeping them down.

The company’s flagship offering can be used as part of integrated pest management (IPM) programs – fitting seamlessly into all IPM programs – to help reduce reproduction and magnify the success of these protocols, or as a standalone solution for customers who want to reduce or eliminate the use of lethal rodent control methods.

In multiple, independent field deployments, ContraPest was shown to reduce rat activity over 90% when added to an existing IPM program.

ContraPest® is registered federally as a General Use Product.

Delivery Systems and New Products

In July 2023, SenesTech began to distribute a new delivery system for ContraPest®, the Isolate Bait System™. This new delivery system brings to market a simple design that enables more efficient deployment, incorporates an enhanced formulation of ContraPest® that is expected to provide improved performance of the fertility control bait in the field and is paired with a new bait station that is more space-efficient and economical.

The other delivery systems available for ContraPest include the Ultimate Bait System™, a tank and tray in a larger format for use with more severe infestations, and the Elevate Bait System™, a unique delivery system that targets above ground infestations, as with roof rats.

SenesTech, as of August 2023, is also in the final stages of releasing a soft bait formulation, which provides the unique attributes of proven fertility control in an industry-familiar format demanded by big box retailers, key e-commerce channels and leading industry pest management professionals.

Market Opportunity

According to SenesTech’s figures, rats cause over $27 billion in damage to public and private infrastructure annually in the United States. Rats also destroy 20% of the global stored food supply every year by consuming or contaminating it.

Rats are known to spread at least 35 diseases, globally posing a dangerous risk to public health and safety. Not only does this age-old problem persist despite extensive campaigns to eradicate it, but multiple sources have reported that post-COVID rat populations have boomed.

Poison-based control methods sicken rats, and they typically die slowly. An animal that eats a poisoned rat may also sicken or die. The global rodenticide market is projected to be worth $1.7 billion by 2026.

In one case study, results reported by the customer showed a $5,000 investment in ContraPest® saved more than $500,000 annually in reduced labor, loss and damage.

Management Team

Joel Fruendt is SenesTech’s President and CEO. He has 15 years of executive leadership in the vector and pest control industries as Vice President and General Manager of Clarke Environmental Inc., a leading vector and pest control products and services company. He has extensive expertise in the development and manufacturing of EPA-registered chemical control products, and the commercialization and sale of those products. He received the ‘Smart Leaders’ award from Smart Business Magazine and holds a bachelor’s degree in business from Illinois Wesleyan University.

Tom Chesterman is CFO at SenesTech. He has over 20 years of experience as the CFO of public companies in the life science, tech and telecommunications industries. Most recently, he was the Vice President and Treasurer of GCI, a telecommunications company. Previous to that, he was the CFO of life science companies Bio-Rad Laboratories, Aradigm and Bionovo. He has a bachelor’s degree from Harvard University and an MBA from the University of California at Davis.

Dan Palasky is Chief Technical Officer at SenesTech. Previously he held the title of Vice President of Research & Development at PLZ Corp., a manufacturer of chemical consumer products, serving as the technical expert for its entire product portfolio. He started his career with Camie-Campbell, Inc., as a chemist in the R&D department. Mr. Palasky received his bachelor’s degree in chemical engineering from the Missouri University of Science & Technology and his MBA in Project Management from Aspen University.

SenesTech Inc. (NASDAQ: SNES), closed Monday's trading session at $0.7001, up 19.6957%, on 1,766,793 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.52/$80.952.

Recent News

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF).

Rare earth elements are critical to the modern economy due to their applications in several key industries. Their unique magnetocrystalline, electrochemical and luminescent properties allow rare earth elements to serve in technology-based sectors, consumer electronics and even national defense systems. This includes purifying semiconductor materials, such as gallium nitride and silicon carbide, and acting as essential raw materials in the permanent magnets used in electric-vehicle motors and wind-turbine generators. With the United States and other major nations looking to transition to electric vehicles over the next few decades, demand for rare earth metals is set to explode. However, with the majority of the world's supply of rare earth metals coming from China, most western nations are looking to build up domestic rare-earth-metal supplies or partner with suppliers from allied nations. In the meantime, western officials are working to figure out the potential ecological consequences of large-scale, rare-earth processing. The strides being made by enterprises such as Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) offer practical case studies of how much progress western countries can make if they focus on nurturing domestic supply chains instead of relying on imports of the needed critical metals.

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) is a critical metals (“CM”) separation technology company executing an ESG-centered plan toward establishing a comprehensive North American critical metals supply chain. The company has developed a transformative commercial-ready technology, RapidSX™, for separating and purifying critical metals. Ucore intends to deploy this technology in pursuit of a CM supply chain independent of China for Western original equipment manufacturers (“OEMs”), most notably in the automotive and renewable energy industries.

Ucore’s vision is to become a leading advanced technology company providing best-in-class metal separation products and services to the mining and mineral extraction industry. Its initial focus is on processing heavy and light rare earth elements (“REEs”), disrupting a supply chain that is dominated by China.

China currently controls about 80% of the world’s access to REE mining projects and over 90% of the world’s REE processing capabilities, and it produces about 95% of the goods containing REE components.


Ucore is working to scale Western supply needs by establishing REE separation and rare earth oxide (“REO”) production capabilities in cooperation with strategic upstream supply and downstream offtake partnerships. The company, along with its industry partners, aims to unlock access to Western REEs for current consumer, energy, manufacturing and military sectors.

By 2025, Ucore expects to commercially separate U.S.-friendly sources of REEs and supply OEMs with REOs required to produce rare earth permanent magnets (“REPMs”) – the essential component of electric motors and generators required to support the world’s transition to electrification and sustainable energy sources.

The company intends to contribute to this initiative through the near-term development of a heavy and light rare-earth processing facility in Louisiana and subsequent development of Strategic Metals Complexes (SMCs) in Alaska and Canada, as well as through the longer-term development of its 100%-owned Heavy Rare Earth Element (HREE) mineral resource property at Bokan Mountain on Prince of Wales Island, Alaska.

Ucore is headquartered in Halifax, Nova Scotia.

Projects & Technology

RapidSX™ Demonstration Plant

The Kingston, Ontario, RapidSX™ Demonstration Plant commissioning process is underway. Once commissioned, the plant is designed to demonstrate the commercial capabilities of the RapidSX technology platform.

The RapidSX demo plant will show:

  • The techno-economic advantages of the RapidSX technology platform
  • The processing of tens of tons of heavy and light mixed rare earth element concentrates in a simulated production environment
  • The platform’s ability to operate for thousands of semi-continuous run-time hours
  • Production of high-purity NdPr, praseodymium, neodymium, terbium and dysprosium rare earth elements for early OEM product qualification trials

The demo plant is located within Ucore’s 5,000-square-foot RapidSX Commercialization and Demonstration Facility and is run by its laboratory partner, Kingston Process Metallurgy Inc. (“KPM”).

RapidSX™ Technology

Innovation Metals Corp., acquired by the company in 2020, developed the RapidSX separation technology platform with early-stage assistance from the United States Department of Defense, later resulting in the production of commercial-grade, separated rare earth elements at pilot scale.

RapidSX combines the time-proven chemistry of conventional solvent extraction (SX) with a new column-based platform that significantly reduces time to completion and plant footprint, as well as potentially lowering capital and operating costs. SX is the international REE industry’s standard commercial separation technology and is currently used by all REE producers worldwide for bulk commercial separation of both heavy and light REEs.

Utilizing similar chemistry to conventional SX, RapidSX is not a “new” technology, but it represents a significant improvement on the well-established, well-understood, proven conventional SX separation technology preferred by REE producers.

Strategic Metals Complex

Ucore, engineering partner Mech-Chem Associates Inc. and KPM are developing the full-scale engineering for the company’s first Strategic Metals Complex (SMC). The SMC is a planned REE separation and rare earth oxide production plant slated to commence construction in Louisiana in 2023. It is scheduled to initially process 2,000 tons of total rare earth oxides by the end of 2024, increasing to 5,000 tons in 2026.

The company has three initial U.S.-friendly feedstock agreements in place for the Louisiana complex, along with multiple developing offtake agreements. It received a C$16 million+ incentive package offer from Louisiana Economic Development to support construction of the SMC.

Bokan-Dotson Ridge REE Deposit

Ucore has invested over C$35 million to establish and validate the Bokan-Dotson Ridge resource in preparation for mine design and permitting. Initial drilling is complete, and a Preliminary Economic Assessment has been issued. Next steps for the project include a feasibility study, detailed mine design and permit acquisition. The project can be “near shovel ready” for construction in less than 30 months after receipt of the next stage of development funding.

Market Opportunity

According to a report by Grand View Research, the global rare earth elements market was valued at $2.8 billion in 2018 and is forecast to reach a value of $5.6 billion by 2025, achieving a CAGR of 10.4% during the period. Market growth is driven by increasing demand for these elements in the manufacturing of magnets and catalysts for the automotive industry. Rising demand for electric vehicles to reduce CO2 emissions is expected to propel the use of permanent magnets in the production of EV batteries.

China is the major producer and consumer of REEs. To maintain self-sufficiency and to meet future demand, China has been raising the export tariffs on rare earth elements shipped to various countries, including the U.S., Japan, India, Brazil and the European Union. This led to the current supply-demand gap in these countries, as they rely on imports from China.

China reduced the exports of REEs by 72% in the second half of 2010 to preserve its reserves of these elements and continues to export REEs at reduced levels, thereby affecting industries such as automotive, oil and gas, and electronics, which require an ample amount of rare earth elements.

Management Team

Pat Ryan, P.Eng., is Chairman and CEO of Ucore Rare Metals. He began as a director with the company when he developed a heightened interest in critical metals. Before joining Ucore, he founded and led a multimillion-dollar automotive OEM design and lean manufacturing company. His understanding of complex supply chains across international markets has led to a prime positioning as the global auto industry transitions to vehicle electrification. He holds a Bachelor of Engineering degree from Dalhousie University.

Peter Manuel is Vice President and CFO of Ucore. Prior to joining the company, he practiced as a Chartered Accountant for more than 17 years, providing consulting services to companies in a range of industries, with a focus on the financial services and resource sectors. He spent 10 years in England and Ireland providing assurance, strategic planning, corporate finance and other consulting services to a portfolio of both public and private entities. He holds a Bachelor of Commerce Degree from Dalhousie University.

Michael Schrider, MEng, P.E., is Vice President and COO of Ucore. He is a multidisciplinary engineer who has been involved in manufacturing, engineering and managing complex structural and mechanical systems projects since 1989. He was the Founder, President and Chief Engineer of Schrider & Associates and Alton Bay Design, both engineering services firms. He holds a bachelor’s degree in naval architecture and marine engineering from the University of New Orleans and a master’s degree in mining, geological and geophysical engineering from the University of Arizona.

Mark MacDonald is Vice President of Investor Relations at Ucore. He has over 25 years of experience implementing award winning business development and marketing programs at regional and national levels. As Vice President of Sales, he was responsible for Mediapro Communication’s growth as AT&T Canada’s leading B2B sales partner. He subsequently became Atlantic Regional Vice President of AT&T Canada Corp. He holds a Bachelor of Commerce degree from Dalhousie University.

Ucore Rare Metals Inc. (UURAF), closed Monday's trading session at $0.5835, up 2.3684%, on 12,796 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.395/$1.15.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene, a late clinical-stage biopharmaceutical company, creates clean-surfaced, catalytically active nanocrystals that directly modulate biological systems, including the central nervous system, by improving mitochondrial health

The company's lead investigational candidate, CNM-Au8(R), is currently in development as a disease-modifying treatment for people living with specific types of neurodegenerative disorders ("ND"), namely amyotrophic lateral sclerosis ("ALS"), Parkinson's Disease, and multiple sclerosis ("MS")

Neurodegenerative disorders are characterized by neurodegeneration – the progressive loss of neuron structure, neuronal functions, and finally, the neurons themselves

Nanotherapeutics are in development to stop or reverse neurodegeneration using novel approaches to address the mitochondrial deficits and bioenergetic crises common to these neurodegenerative diseases

Also known simply as nerve cells, neurons are central to most – if not all – of the body's normal functions, from breathing and talking to eating, thinking, and walking ( They support these activities by sending and receiving information between the brain and muscles, and are also responsible for receiving sensory input from the external environment and relaying that information to the brain. The therapeutic potential of nanoparticles has piqued the interest of Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on the discovery and development of innovative, life-changing medicines for people with serious and life-threatening diseases. The company has created and refined a proprietary electro-crystallization-method that results in clean-surfaced, catalytically active nanocrystals that directly modulate biological systems, including the central nervous system, by improving mitochondrial health.

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.


CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Monday's trading session at $0.4985, up 18.634%, on 718,628 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3538/$1.99.

Recent News

Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF)

The QualityStocks Daily Newsletter would like to spotlight Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF).

Appia (CSE: API) (OTCQX: APAAF) (FSE: A0I0) today unveiled its new corporate website, which better presents project milestones and company information. The newly designed site includes a dedicated projects landing page, updated corporate presentation and fact sheet that prominently highlights the substantial strides Appia has made on its rare earth element ("REE") and uranium projects in Canada and REE Ionic Adsorption Clay ("IAC") project in Brazil, providing insights into both current and historical endeavors. "Our website redesign is not just about aesthetics; it's a window into the depth of our commitment and progress," said Tom Drivas, CEO of Appia Rare Earths & Uranium Corp. "We want our stakeholders to easily navigate through the rich tapestry of our ventures, and the enhanced site achieves precisely that. Appia would like to extend a heartfelt appreciation to our incredibly talented website design team for their unwavering dedication and tireless efforts in transforming our vision into a tangible reality."

To view the full press release, visit

Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) is a mineral exploration company focused on exploration activities at its newly acquired Cachoeirinha rare earths project (“PCH Project”) in Brazil, as well as delineating high-grade critical rare earth elements (REE) and gallium at its Alces Lake property in Saskatchewan. Other properties in Appia’s portfolio include its Elliot Lake Property in Ontario’s historic mining camp, with a large NI 43-101 uranium and rare earths resource. Fully funded with over $5 million (CDN) in cash, no debt, aggressive exploration currently underway, and experienced management, Appia is progressing rapidly on multiple fronts in highly desired market sectors.

The company is headquartered in Toronto, Canada.


PCH Project-Brazil

The PCH project hosts REE mineralization in both ionic clays developed from the weathering of alkaline granites and in-situ rare earth mineralization associated with the underlying granite and a carbonatite intrusion to depths greater than 100 meters. Sampling data shows enrichment in rare earth minerals to depths of between eight meters and +30 meters.

In early 2023, Appia announced a definitive agreement to acquire a 70% interest in the PCH Project, which is 17,551 hectares in size and located in the Tocantins Structural Province of the Brasília Fold Belt, Goiás State, Brazil. It is classified as an alkaline intrusive rock occurrence with the potential for highly anomalous REE and Niobium mineralization.

The region around Iporá, a city located roughly 30 km from the PCH Project, has significant mineral exploration and mining activity and well-developed infrastructure.

In July 2023, Appia commenced an aggressive auger and reverse circulation (RC) drill campaign to delineate a potential resource estimate at the PCH project. Initial results at the site revealed significant exploration potential with impressive values that often surpass known ionic clay deposits in Brazil, particularly for the highly valuable heavy rare earths Terbium and Dysprosium.

The auger holes drilled at Target 4 have exhibited a range of total REE grades, ranging from 274 ppm to 16,648 ppm (1.66%), with an average of 1,291 ppm total REE. The valuable rare earths used in magnet applications – praseodymium, neodymium, terbium and dysprosium (Pr, Nd, Tb, and Dy) plus yttrium (Y) accounted for approximately 14% of total rare earths, reaching a maximum of 28.4%. Notably, the deposit also contains anomalous values of niobium and scandium, with average values of 736 ppm for Nb and 62 ppm for scandium in a composite sample from Target 4.

Heavy rare earths (HREEs) show maximum values of 1,624 ppm and average values of 1,291 ppm, primarily as terbium and dysprosium. Light rare earths (LREEs) show maximum values of 14,024 ppm (1.54%) with an average of 1,145 ppm. Neodymium and praseodymium, the main magnetic light rare earths, show respective maximum values of 3,131 ppm (Nd) and 885 ppm (Pr) and average values of 216 ppm (Nd) and 61.7 ppm (Pr). The overall HRRE/LREE ratio has a maximum of 39.5% and an average value of 16.67%.

“Appia is thrilled with the progress made and the promising results thus far,” CEO Tom Drivas stated in a news release. “The company remains committed to advancing its exploration plans, aiming to promptly gather significant data throughout the year, and to work towards estimating a maiden mineral resource in the coming months.”

Alces Lake Project – Saskatchewan

Appia’s Alces Lake project, located in northern Saskatchewan, encompasses some of the highest-grade total and critical REEs and gallium mineralization in the world, hosted within several surface and near-surface monazite occurrences that remain open at depth and along strike.

Following the company’s acquisition of additional new mineral claims in the area in February 2023, Appia’s Alces Lake claim block now totals 38,522 contiguous hectares (95,191 acres) – 100% owned by the Company.

Appia announced the completion of a NI43-101 technical report on the property in June 2023, providing an update on exploration previously reported in March 2021.The report is available on SEDAR under the company’s profile.

Extensive diamond drilling and geophysics surveys are underway to explore a more than 25-kilometer structural corridor. In July 2023, the company issued an update on its diamond drill program having completed the first phase of drilling at the project’s Magnet Ridge Zone to further test the extent of the mineralization to the south south-east (SSE). President Stephen Burega noted the presence of “continued mineralization at significantly thicker intercepts.”

As part of its 2023 exploration program at Alces Lake, Appia plans to target priority areas that extend SSE from the Wilson, Richard, Charles, Bell, Ivan, Dylan, Dante and AMP zones through the Magnet Ridge Zone and beyond, covering an area extending approximately 20 kilometers in length and 5 to 7 km in width. Appia will also undertake reconnaissance drilling on priority regional geological and geophysical targets in the Western Anomaly area.

Other Projects

  • Appia holds a total of 75,314 hectares (186,106 acres) of land on four uranium claim blocks in the prolific Athabasca Basin (Loranger, North Wollaston, Eastside and Otherside). Exploration plans for these properties are expected to be announced once permits are in hand.
  • Appia also has a 100% interest in 12,545 hectares (31,000 acres), with rare earth element and uranium deposits over five mineralized zones, in the Elliot Lake Camp, Ontario.

Market Opportunity

A report from Mordor Intelligence forecasts the global REE market is expected to grow from 168 million tons in 2023 to 206.25 million tons by 2028, marking a CAGR of 4.19% during the forecast period. The market is gradually improving following the economic and production restrictions of the COVID-19 pandemic.

Factors driving the market’s growth include high demand from emerging economies and the dependency of environmentally friendly technologies on rare earth elements.

According to UxC, one of the nuclear industry’s leading market research and analysis companies, the uranium market is rapidly becoming production-driven, where spot and long-term prices more closely correlate to the marginal cost of uranium production.

Although global reactor requirements are projected to be flat through 2024, UxC forecasts that significant demand growth from 2025 to 2040 will necessitate new production as resources are exhausted at several uranium projects. In addition, a large percentage of production exists in regions of the world with high geopolitical risk, which makes the market vulnerable to future disruptions and price volatility.

Management Team

Tom Drivas is CEO of Appia Rare Earths & Uranium Corp. He is an entrepreneur with over 30 years of experience in various industries, including over 20 years in the mineral resource industry. He is also currently a director of Romios Gold Resources Inc., a publicly traded company he founded in 1995.

Stephen Burega is President of Appia. He brings 16 years of management and operations experience in the mining and natural resources sectors. His extensive emerging markets background, along with a deep understanding of stakeholder management, social development and structured community engagement, position him well to lead Appia’s First Nations community engagements. He is also President and CEO of Romios Gold Resources which is focused on base and precious metal exploration in North America.

Frank van de Water is the company’s CFO. He holds CPA and CA designations and has been involved with international mining, metals and resource companies in North America, Latin America, Europe and Africa for more than 40 years.

Dr. Irvine R. Annesley, Ph.D., is VP Exploration at Appia. He is a licensed geoscientist (P.GEO.) and Professor in Economic (Mining and Mineral Exploration) Geology at École Nationale Supérieure de Géologie in France and an Adjunct Professor in Geology at the University of Saskatchewan. He has over 35 years of global exploration and applied research experience in uranium, gold and base metals exploration, most recently with Athabasca uranium explorer JNR Resources Inc.

Don Hains, P.Geo., is the company’s Consulting Geologist and Qualified Person Consulting Industrial Minerals Expert.

Antonio Vitor is Appia’s Country Manager, Brazil. He has a track record as a portfolio manager and board member. He has held multiple significant positions, including Territory Manager at Shell, as well as Senior Project Planning and Consulting roles at PwC and Petrobras.

Jack Lifton is the company’s Senior Technical Advisor and Consultant. He is an author and lecturer on the market fundamentals of technology metals.

Appia Rare Earths & Uranium Corp. (OTCQX: APAAF), closed Monday's trading session at $0.17992, up 1.6038%, on 58,080 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.075/$0.272.

Recent News


The QualityStocks Daily Newsletter would like to spotlight GEMXX Corp. (OTC: GEMZ) .

GEMXX Corporation is a Las Vegas-based jewelry maker developing its strategic gold metal and ammolite gemstone from a unique mine-to-market product pipeline

Gold has enjoyed record high prices during a "roaring 2023" run, and price fluctuations surrounding those highs have failed to deter optimism that demand for the precious metal may remain during the coming year

GEMXX is the only publicly traded ammolite gemstone company in the world, and plans to expand its gemstone and jewelry production by 300 percent next year

The company reported upbeat earnings and no long-term debt in its recent Q2 financial statement

With the close of its 2023 mining test season, mine-to-market jewelry enterprise GEMXX (OTC: GEMZ) is celebrating positive outcomes from its mine assessment, debt management practices, and revenue operations, as it prepares for further growth in 2024. GEMXX reported upbeat earnings during its Q2 statement published Nov. 21, stating that its account receivables rose from $701,252 to $1.3 million YOY, total assets increased to $20.1 million, and net income grew from $132,842 to $212,526 — all while maintaining no long-term debt ( The company is led by an executive team with over 160 years of combined experience in the market, and gold's continued demand strength has provided GEMXX's leadership with encouragement as it pursues its long-term strategy.

GEMXX Corp. (OTC: GEMZ) is a mine-to-market enterprise specializing in gold, gemstone, and jewelry production. With ownership of mining resources, production facilities, and operational assets, the company maintains control over every aspect of its production process, from gold mining and gemstone extraction to jewelry manufacturing and global distribution.

As a prominent player in the industry, GEMXX stands out as a leading producer of high-quality finished Ammolite jewelry. Notably, it holds the distinction of being the sole public company engaged in Ammolite mining worldwide. In addition to its Ammolite operations, the company is actively involved in gold mining and prides itself on its ability to design and manufacture exquisite jewelry pieces and exceptionally rare, natural fossil decor items for clientele around the globe.

One of GEMXX’s key advantages lies in mining its own gold reserves to be utilized in its jewelry production. This strategic approach provides the company with a cost-saving edge over other producers in the market.

Ammolite is similar to black opal and is a biogenic gem like amber and pearl. It is derived from the fossilized shells of ammonites, a group of extinct marine nautiluses.

GEMXX’s world class gemstone cutters and jewelry designers are continuously leading the Ammolite industry. Its team believes in the company’s philosophy, vision and goals, and works every day to continue to drive the Ammolite industry to the forefront of the gem world.

The company has offices in Las Vegas and Hong Kong.

Projects and Operations

GEMXX has formulated an ambitious growth plan that, while challenging, is deemed attainable. The company’s strategy revolves around bolstering its market share through several key initiatives. Firstly, GEMXX aims to strengthen its position in current markets by nurturing and expanding existing relationships with customers and partners.

Secondly, the company plans to venture into untapped markets strategically. By identifying and targeting new areas, GEMXX seeks to establish a presence in regions that present promising opportunities for growth.

Additionally, GEMXX envisions growth through acquisitions. By considering and integrating key services, distribution networks and retail outlets into its fold, the company aims to consolidate its market position and capitalize on synergies for enhanced success.

To cater to the rising demand for its products, GEMXX has placed a primary focus on increasing gemstone production. The company’s southern properties, situated in Alberta, Canada, hold valuable deposits of rough Ammolite gemstone. By tapping into these resources, GEMXX is poised to meet the demand for its exquisite gemstone products and further fuel its expansion plans.


GEMXX possesses significant mineral assets in the form of a Mineral Work Permit covering an 800-acre area and two Ammonite Shell Mineral agreements encompassing 217 acres within the same region. The company’s management effectively operated mines in close proximity to these properties. Moreover, core sampling, along with fossil outcroppings on the riverbanks, confirms a substantial Ammolite resource present in these designated areas.

Both the Mineral Work Permit and the Ammonite Shell Mineral agreements grant GEMXX unrestricted access to all Ammolite resources within their respective demarcations. Notably, the company is not obligated to pay any royalties to third parties, thereby enabling GEMXX to fully capitalize on the potential of these valuable resources.

Furthermore, there are no stringent regulatory conditions that GEMXX must fulfill to gain or retain access to the Ammolite deposits. This freedom of access allows the company to proceed with its mining and production operations unimpeded, providing an advantageous position for future growth and success.

In March 2023, GEMXX made a significant announcement, revealing its acquisition of a 50% ownership stake in Crazy Horse Mining Inc., a Canadian gold mining company with assets situated in the province of British Columbia. As part of this deal, Crazy Horse’s assets, which encompass a 100% interest in two gold projects, called Snow Creek and Rosella Creek, spread across a substantial area exceeding 700 acres, now become part of GEMXX’s portfolio.

Under the terms of this strategic partnership, GEMXX and Crazy Horse will jointly share the expenses related to mining operations on these projects. Additionally, the two companies will share the gold produced from these ventures, leading to a collaborative and mutually beneficial arrangement.

Initial tests conducted on the property, combined with gold already recovered this season, confirm all expectations for the claims and substantiate the company’s estimated extraction target of over 100,000 ounces of easily recoverable gold. To validate and provide a more comprehensive assessment of this estimate, an S-K 1300-compliant Resource Report is scheduled to be conducted during the summer of 2023.

By acquiring this stake in Crazy Horse Mining Inc., GEMXX has positioned itself for further growth in the gold mining sector and is poised to capitalize on cost of goods savings in its jewelry business.

Market Opportunity

Leading independent market research companies such as Data Monitor and GIA estimate the worldwide market for luxury or premium lifestyle products, which include gems and jewelry, at over $90 billion annually and growing. Ammolite sales around the world have seen unprecedented growth over the past 20 years. Worldwide retail sales are now estimated to be over $100 million.

Ammolite jewelry and fossils are featured aboard cruise ships and can be found in specialty shops in almost every cruise port in North America. Asian markets have grown since feng shui master Edward Li called Ammolite the most influential stone of the new millennium, referring to it as the “Seven Color Prosperity Stone.” Home shopping channels in Japan, Australia, France, Germany, the UK, Canada and the U.S. have all featured Ammolite jewelry.

Ammolite and ammonites can also be found on many ecommerce sales platforms, including Amazon, eBay and Etsy. Ammolite is sold around the world in tourist and traditional jewelry markets. The company has established customers in home shopping channels, cruise tourism, jewelry retailers, Asian feng shui markets, Asian retail markets and ecommerce platforms.

Management Team

With over 160 years in Ammolite management, operations, and sales, GEMXX possesses an unparalleled wealth of knowledge and expertise. Its team members have extensive backgrounds in every facet of the Ammolite business, allowing the company to excel in product development, maintain rigorous quality control measures, and maximize profitability. The breadth and depth of the GEMXX team’s experience enable the company to navigate the industry with precision, ensuring that GEMXX remains at the forefront of the Ammolite market. GEMXX leverages its collective wisdom to drive innovation, deliver exceptional products, and optimize business strategies to achieve long-term success.

Jay Maull is Founder, CEO and Chairman of GEMXX. With a career spanning more than three decades, he has been deeply involved in the Ammolite industry, from mining and production to marketing. He has owned and operated the world’s largest Ammolite mine and has delivered exceptional Ammolite products to customers across all continents. He has also established the world’s largest Ammolite ecommerce platform.

Richard Clowater is President of GEMXX. He is a skilled sales and marketing professional with a focus on research, data analysis and strategic planning. He has successfully implemented initiatives to expand markets, boost profits and foster customer loyalty. He has an impressive track record of negotiating sales and contracts worth over $250 million with influential stakeholders, including key purchasing personnel, C-suite executives and government entities at all levels.

Tom Dryden is a Vice President of GEMXX and brings a wealth of experience and expertise to the production and marketing of Ammolite, spanning over 30 years. His extensive involvement in the industry has granted him unparalleled knowledge of the Bearpaw Ammonite bearing formations. As a recognized authority in the field, Mr. Dryden’s research and papers on Canadian Ammonites have garnered global recognition, being published worldwide. In his role at GEMXX, Mr. Dryden assumes the responsibility of overseeing the company’s Canadian-based production facilities. 

P. K. Chung is Business Manager Asia at GEMXX. With a track record of over 25 years in Ammolite business management, production and marketing in Asia, she is a recognized authority in the industry. Based in the Hong Kong gem district, she possesses an intricate understanding of the Asian gem and jewelry markets, including market dynamics, consumer preferences and industry trends specific to the region. Her strategic insights and deep connections enable GEMXX to thrive in this influential market.

GEMXX Corp. (OTC: GEMZ), closed Monday's trading session at $0.0298, up 2.9361%, on 11,716 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.023/$0.998.

Recent News

Horizon Fintex | Upstream

The QualityStocks Daily Newsletter would like to spotlight Horizon Fintex | Upstream

A recent blog written by Fernanda De La Torre highlights Upstream, the next-generation exchange and retail securities trading app, and invites Australia-based issuers seeking to expand reach to a global audience to dual list. Upstream provides dual listing capabilities to Australian issuers on all the major exchanges including ASX (Australian Securities Exchange), NSX (National Stock Exchange of Australia) and more. In addition, as part of MERJ, an overseas national securities exchange, qualified issuers may fast-track listing on Upstream. The piece covers a number of reasons why dual listing is encouraged, including Upstream's ability to offer ASX, NSX and other issuers a complementary market that aligns with their interests. De La Torre further explains, "The benefits and methodologies of Upstream dual listings may directly increase Australian issuers' global shareholder base, market capitalization and liquidity while giving global investors the opportunity to access and invest in interesting Australian companies."

To view the full blog, visit

Horizon Fintex is a software business specializing in compliant securities solutions. The company aims to facilitate the future of capital markets by leveraging the regulatory experience of Wall Street bankers and the proven track record of technology veterans to bring focus to compliance, efficiency, security and transparency.

Horizon’s flagship product is the revolutionary trading app ‘Upstream’, a MERJ Exchange Market, and the first regulated market powered by a blockchain to offer both digital securities and NFT trading. Upstream traders experience T+0 settlement, best bids and offers displayed on a transparent public orderbook that prevents predatory market practices – all from a user-friendly trading app.


Horizon Fintex offers a full suite of end-to-end blockchain-enhanced software solutions to create a seamless experience for both issuers and investors. Its product suite includes:

  • Securitization & IssuanceETSware is an end-to-end Electronic Trading System streamlining capital raising from primary issuance through compliant secondary trading.
  • KYC Compliance OnboardingKYCware is a white label Know Your Customer (KYC) and Anti-Money Laundering (AML) compliance software solution offering best-in-class cryptographic security to compliantly onboard and verify user identity through a smartphone application.
  • AML Screening SoftwareAMLCop offers advanced Anti-Money Laundering (AML) software to streamline the verification of user details against a proprietary database of global sanctions, politically exposed persons (PEPs) and watchlists.
  • Cap. Table Management ToolsCustodyWare equips registered U.S. transfer agents with next-generation cap. table management software to manage securities on behalf of their clients pursuant to an SEC-registered or exempt securities offering.
  • Exchange & Trading App TechnologyOpen Order Book offers Ethereum blockchain securities exchange software to power the next generation of trading venues for digital assets.

Upstream – The Horizon-Powered Trading App

Upstream is a joint venture with MERJ Exchange (, an affiliate of the World Federation of Exchanges.

Upstream aims to be the premiere global trading hub offering issuers around the world exposure to a digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD (fiat) to increase liquidity and enhance price discovery; while also offering investors access to dual-listed companies, IPOs, crowdfunded companies, U.S. & Int’l. equities, digital coupons and NFTs directly from a user-friendly trading app.

Upstream aims to unlock liquidity for investors of all levels while offering industry-leading levels of transparency, accessibility and investor protections enforced using Ethereum blockchain technology.

Management Team

Brian Collins is the CEO of Horizon Fintex. He founded the company in 2010. From 1999-2010, Mr. Collins was CEO of Abbey Technology in Switzerland, specializing in the design of trading software for Swiss banks. Prior to this, he worked for Credit Suisse in Zürich, designing and building proprietary equity trading solutions. Mr. Collins graduated in 1990 with a BS in Computer Systems from the University of Limerick, Ireland.

Mark Elenowitz is the company’s President. He is a Wall Street veteran with over 29 years of experience. Mr. Elenowitz was the co-founder of a U.S. broker dealer and is Managing Director of two U.S. broker dealers, responsible for advising clients on compliance, capital structure and capital market navigation. He was responsible for leading the first successful Reg A+ IPO of a company to list on the NYSE and others which listed directly onto Nasdaq. He is a noted speaker at Small Cap and Reg A events, including the SEC Small Business Forum, and has been profiled in BusinessWeek and CNBC, as well as several other publications. Mr. Elenowitz is a graduate of the University of Maryland School of Business and Management with a BS in Finance and holds Series 24, 62, 63, 79, 82 and 99 licenses.

Dr. Andrew Le Gear is the CTO of Horizon Fintex. Prior to joining the company in 2013, he worked as a software engineer with Dell Inc. (2012-2013) and Lehman Brothers and Nomura Plc. (2007-2012). Dr. Le Gear was a co-founder of Juneberi Ltd., a research-driven software tech start-up (2004-2007). He graduated in 2006 with a Ph.D. in Computer Science from the University of Limerick, Ireland.

Peter Hall is the company’s CIO. Prior to joining Horizon Fintex in 2011, he worked at Microsoft (2008-2011), Atos Origin (2004-2008) and AIT Group Plc. (1998-2002). Mr. Hall has held CISSP certification since 2010. He graduated from the University of Sheffield, UK in 1995 and earned an MS from the University College London in 2006.

Mike Boswell is the CFO of Horizon Fintex. A Wall Street veteran, he co-founded a U.S. broker dealer and served as Chief Compliance Officer. Mr. Boswell was also Managing Director of TriPoint Capital Advisors, a merchant banking and financial consulting company, and CFO of Mission Solutions Group, a privately held defense sector firm. He earned an MBA from John Hopkins University and a BS in Mechanical Engineering from the University of Maryland. Mr. Boswell holds Series 24, 62, 63, 79, 82 and 99 licenses.

Recent News


Correlate Energy Corp. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Energy Corp. (OTCQB: CIPI).

Correlate Energy (OTCQB: CIPI), a growth-oriented distributed energy company, has successfully completed the commissioning of a solar project for American Tire Distributors ("ATD"). The project is located at ATD headquarters in Huntersville, North Carolina. Correlate Energy and ATD collaborated on the rooftop solar project, which reflects ATD's commitment to operate in an environmentally responsible way. The announcement noted that, in addition to the environmental benefits, the system is projected to result in substantial cost savings for ATD by reducing the company's reliance on traditional energy sources. Specifically, the company anticipates that during the next two decades, the innovative solar system will reduce CO2 emissions by an estimated 5,463 tons, which is the equivalent of emissions produced by some 12,442,130 miles of car travel. ATD has more than 120 distribution centers nationwide. "We are thrilled to unveil this remarkable project, reflecting our dedication to providing clients with best-in-class sustainability solutions and reducing their carbon footprint," said Correlate Energy CEO Todd Michaels in the press release. "Completing this project at another nationally recognized headquarters building is a major milestone as this initiative showcases the powerful link between sustainability and profitability."

To view the full press release, visit

Correlate Energy Corp. (OTCQB: CIPI) is a publicly-traded company strategically positioned to capitalize on America’s unstoppable trend toward decentralized energy generation.

The energy grid in the U.S. is insufficient for the booming clean energy trend, and current infrastructure is limiting green energy distribution. Constructing the needed infrastructure to address this demand imbalance will cost billions and be far too slow, positioning decentralized systems, like those on offer from Correlate, in a key position for heightened demand.

Correlate has identified several key economic drivers powering the decentralized energy trend, including:

  1. Real Cost Savings – Customer pays zero money down and gets an instant electrical price discount to current rates.
  2. Massive Project Investment Funding – The International Energy Agency estimates that over one billion dollars per day will be invested in solar energy in 2023.
  3. Consistent Long-Term Incentives – The Inflation Reduction Act is a game-changer, supercharging renewables with $1.2 trillion in tax credits for 10 years of market support.
  4. Robust Customer Demand – Wood Mackenzie expects the U.S. solar industry to nearly triple in size over the next five years.

Correlate’s team of multi-decade experts who have worked with renowned global brands are positioning the company to make the most of this opportunity while consolidating a fragmented industry. Collectively, the team has developed, financed and deployed over $2 billion in clean energy projects to date.

Three-Pronged Strategy

Correlate is leveraging a three-pronged strategy aimed at driving shareholder value:

  1. Sell – Correlate seeks to finance, develop and profitably sell localized clean energy solutions and microgrids to industrial, commercial and residential customers.
  2. Retain – Correlate plans to retain ownership of some of these energy systems and thereby realize ongoing, reliable cash flow.
  3. Acquire – Correlate seeks to acquire proven renewable energy companies in order to exponentially grow earnings per share for investors.

This strategy is enhanced by current investment trends. Clean energy earnings are being sought after by investors. In Q4 2022, the median EBITDA multiple for green energy companies was 12.3x, according to Finerva.

Market Outlook

Over the next decade and beyond, renewable energy growth is expected to come primarily via decentralized systems like those offered by Correlate.
The Inflation Reduction Act enacted in late August 2022 is likewise expected to drive growth for the company by providing new tax incentives that reduce costs for clients and/or elevate returns to investors.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings, yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which are very different from traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue, known as the ‘split incentive’, unlocking the majority of the addressable market.

A key portion of Correlate’s strategy relates to consolidation of what has been a fragmented industry. By uncovering opportunities to improve efficiencies through strategic M&A activities, the company intends to enhance profitability throughout its operations.

Management Team

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

Dave Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jed Freedlander is the company’s Chief Development Officer. He has a background in infrastructure development and investment and a strong legal, commercial and finance acumen. Mr. Freedlander has a proven track record in leading complex public-private partnership (P3) and energy transactions and is instrumental in driving Correlate’s strategic development initiatives.

Roger Baum is Executive VP Operations at Correlate. With over 20 years of experience at Core Construction, he brings to the company a wealth of knowledge and a strong track record in delivering successful commercial construction projects.

Jason Loyet is Director of Solar Energy for Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Correlate Energy Corp. (OTCQB: CIPI), closed Monday's trading session at $1.45, off by 0.684932%, on 1,385 volume. The average volume for the last 3 months is 5,826 and the stock's 52-week low/high is $0.3501/$2.35.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced a recommendation from the independent Data Safety Monitoring Board ("DSMB") regarding Berubicin, the company's investigational agent. According to the announcement, the DSMB recommends that CNS Pharmaceuticals' ongoing global, potentially pivotal trial of Berubicin for the treatment of glioblastoma multiforme ("GBM") continue without modification. The company also noted that it anticipated enrollment for the trial to be complete in the first quarter of 2024. The Berubicin study is a multicenter, open-label, randomized controlled study evaluating adult patients with recurrent GBM (WHO Grade IV) where standard first-line therapy has failed, compared to Lomustine. Berubicin is an anthracycline, which is a class of anticancer agents among the most powerful chemotherapy drugs and that are effective against more types of cancer than any other class of chemotherapeutic agents. "Having successfully reached this milestone, we believe that this recommendation reflects Berubicin's acceptable efficacy and safety profile, as defined in the trial protocol, as of the interim analysis," said CNS Pharmaceuticals CEO John Climaco in the press release. "Building on the foundation of strong enrollment laid by our team, our investigators and their patients, the independent findings of the DSMB add to the phase 1 trial data, where 44% of treated patients received a clinical benefit of stable disease or better. Finding an effective treatment for GBM remains one of the great challenges in oncology, and more meaningful options for the many patients who fail first-line therapy are still desperately needed after decades of research. With this recommendation to continue the study, our long-held belief that Berubicin will ultimately address the unmet clinical need of GBM patients now moves closer to becoming reality."

To view the full press release, visit

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Monday's trading session at $1.33, off by 23.1214%, on 571,676 volume. The average volume for the last 3 months is 86,750 and the stock's 52-week low/high is $0.6105/$4.40.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, adjourned its Special Meeting of Stockholders, which convened on Dec. 15, 2023; the meeting is slated to begin today at 9:30 a.m. PT. According to the announcement, the decision to adjourn the meeting was made to provide time to solicit proxies regarding a proposal that had been submitted to stockholders for approval. The company noted that the proposal, Proposal 1, seeks stockholder approval to amend the company's certificate of incorporation to effect a reverse stock split of MULN's outstanding common stock at an exchange ratio between 1-for-2 to 1-for-100; the specific ratio will be determined by the company's board of directors. The announcement stated that the primary focus of the reverse stock split proposal is to increase the per-share market price of Mullen's common stock in order to comply with NASDAQ's requirement to have a closing bid price of $1 or more per share for a minimum of 20 consecutive trading sessions on or before Jan. 22, 2024, and to maintain its listing on the NASDAQ Capital Market. "During the period of adjournment, the company and its proxy solicitor, Okapi Partners LLC, will continue to solicit votes from the company's stockholders with respect to the reverse stock split proposal," the company stated in the press release. "Stockholders can attend the reconvened Special Meeting on Dec. 18, 2023, via the same meeting link as set forth in the Definitive Proxy Statement filed with the Securities and Exchange Commission on Nov. 8, 2023."

To view the full press release, visit

American multinational firm Starbucks has officially entered the electric-vehicle business with the launch of dozens of new EV charging stations at 15 locations between Denver and Seattle. The installation is part of a partnership between Starbucks and Swedish carmaker Volvo that will see the two companies install 50 Volvo charging stations at Starbucks locations in Utah, Colorado, Oregon, Washington and Idaho. Any electric vehicle, regardless of brand, will be able to charge at the Volvo charging stations as long as they have CHadeMO or CCSI connectors. Both companies announced the charging station project in 2022 as part of efforts to mitigate the lack of proper public electric-vehicle charging infrastructure in North America. Compared to the nation's current fleet of 2.3 million electric cars, the Unites States has only 32,000 DC fast chargers. As the charging infrastructure improves, there is likely to be an uptick in the sales of various EV models from automakers such as Mullen Automotive Inc. (NASDAQ: MULN) and other startups as the concerns about EV charger availability are addressed by state actors and private companies.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Monday's trading session at $0.1122, off by 22.6207%, on 102,066,275 volume. The average volume for the last 3 months is 47.524M and the stock's 52-week low/high is $0.1001/$107.4375.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.